Advertisement

Harnessing Chemoselective Imine Ligation for Tethering Bioactive Molecules to Platinum(IV) Prodrugs

  • Daniel Yuan Qiang WongEmail author
Chapter
  • 282 Downloads
Part of the Springer Theses book series (Springer Theses)

Abstract

Platinum(II)-based drugs, namely cisplatin, carboplatin and oxaliplatin, are the first line of treatment for many types of malignancies, including testicular, ovarian and lung cancer (Kelland in Nat Rev Cancer 7:573–584, [1]; Abu-Surrah and Kettunen in Curr Med Chem 13:1337–1357, [2]). However, their efficacy is severely limited by adverse side-effects due to high toxicities and incidences of drug resistance, either inherent or acquired (Fuertes et al. in Chem Rev 103:645–662, [3]).

Keywords

Platinum Imine Proton NH4OAc Buffer Crude Reaction Mixture Oxime Bond Formation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

References

  1. 1.
    Kelland, L.: The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573–584 (2007)CrossRefPubMedGoogle Scholar
  2. 2.
    Abu-Surrah, A.S., Kettunen, M.: Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Curr. Med. Chem. 13, 1337–1357 (2006)CrossRefPubMedGoogle Scholar
  3. 3.
    Fuertes, M.A., Alonso, C., Pérez, J.M.: Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 103, 645–662 (2003)CrossRefPubMedGoogle Scholar
  4. 4.
    Galanski, M., Keppler, B.K.: Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anti-Cancer Agents Med. Chem. 7, 55–73 (2007)CrossRefGoogle Scholar
  5. 5.
    Sternberg, C.N., Whelan, P., Hetherington, J., Paluchowska, B., Slee, P.H.T.J., Vekemans, K., Van Erps, P., Theodore, C., Koriakine, O., Oliver, T., Lebwohl, D., Debois, M., Zurlo, A., Collette, L.: Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68, 2–9 (2005)CrossRefPubMedGoogle Scholar
  6. 6.
    Lemma, K., Sargeson, A.M., Elding, L.I.: Kinetics and mechanism for reduction of oral anticancer platinum(IV) dicarboxylate compounds by L-ascorbate ions. J. Chem. Soc. Dalton Trans. 7, 1167–1172 (2000)CrossRefGoogle Scholar
  7. 7.
    Hall, M.D., Hambley, T.W.: Platinum(IV) antitumour compounds: their bioinorganic chemistry. Coord. Chem. Rev. 232, 49–67 (2002)CrossRefGoogle Scholar
  8. 8.
    Barnes, K.R., Kutikov, A., Lippard, S.J.: Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem. Biol. 11, 557–564 (2004)CrossRefPubMedGoogle Scholar
  9. 9.
    Giandomenico, C.M., Abrams, M.J., Murrer, B.A., Vollano, J.F., Rheinheimer, M.I., Wyer, S.B., Bossard, G.E., Higgins, J.D.: Carboxylation of kinetically inert platinum(IV) hydroxy complexes. An entree into orally active platinum(IV) antitumor agents. Inorg. Chem. 34, 1015–1021 (1995)CrossRefPubMedGoogle Scholar
  10. 10.
    Galanski, M., Keppler, B.K.: Carboxylation of dihydroxoplatinum(IV) complexes via a new synthetic pathway. Inorg. Chem. 35, 1709–1711 (1996)CrossRefPubMedGoogle Scholar
  11. 11.
    Galanski, M., Keppler, B.K.: Carboxylation of dihydroxoplatinum(IV) complexes with acyl chlorides. Crystal structures of the trans-R, R- and trans-S, S-isomer of (OC-6-33)-bis(1-adamantanecarboxylato)-(cyclohexane-1,2-diamine)dichloroplatinum(IV). Inorg. Chim. Acta 265, 271–274 (1997)CrossRefGoogle Scholar
  12. 12.
    Lee, E.J., Jun, M.-J., Lee, S.S., Sohn, Y.S.: Synthesis, structure, and properties of isopropylidenemalonatoplatinum(IV) complexes. Polyhedron 16, 2421–2428 (1997)CrossRefGoogle Scholar
  13. 13.
    Ali, M.S., Ali Khan, S.R., Ojima, H., Guzman, I.Y., Whitmire, K.H., Siddik, Z.H., Khokhar, A.R.: Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3 · H2O. J. Inorg. Biochem. 99, 795–804 (2005)CrossRefPubMedGoogle Scholar
  14. 14.
    Hambley, T.W., Battle, A.R., Deacon, G.B., Lawrenz, E.T., Fallon, G.D., Gatehouse, B.M., Webster, L.K., Rainone, S.: Modifying the properties of platinum(IV) complexes in order to increase biological effectiveness. J. Inorg. Biochem. 77, 3–12 (1999)CrossRefPubMedGoogle Scholar
  15. 15.
    Ang, W.H., Khalaila, I., Allardyce, C.S., Juillerat-Jeanneret, L., Dyson, P.J.: Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J. Am. Chem. Soc. 127, 1382–1383 (2005)CrossRefPubMedGoogle Scholar
  16. 16.
    Reithofer, M.R., Valiahdi, S.M., Galanski, M., Jakupec, M.A., Arion, V.B., Keppler, B.K.: Novel endothall-containing platinum(IV) complexes: Synthesis, characterization, and cytotoxic activity. Chem. Biodivers. 5, 2160–2170 (2008)CrossRefPubMedGoogle Scholar
  17. 17.
    Dhar, S., Lippard, S.J.: Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc. Natl. Acad. Sci. U. S. A. 106, 22199–22204 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ang, W.H., Pilet, S., Scopelliti, R., Bussy, F., Juillerat-Jeanneret, L., Dyson, P.J.: Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: Influence of the ligands on drug efficacies and uptake. J. Med. Chem. 48, 8060–8069 (2005)CrossRefPubMedGoogle Scholar
  19. 19.
    Perez, J.M., Camazón, M., Alvarez-Valdes, A., Quiroga, A.G., Kelland, L.R., Alonso, C., Navarro-Ranninger, M.C.: Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells. Chem.-Biol. Interact. 117, 99–115 (1999)CrossRefPubMedGoogle Scholar
  20. 20.
    Reithofer, M., Galanski, M., Roller, A., Keppler, B.K.: An entry to novel platinum complexes: Carboxylation of dihydroxoplatinum(IV) complexes with succinic anhydride and subsequent derivatization. Eur. J. Inorg. Chem. 2006, 2612–2617 (2006)CrossRefGoogle Scholar
  21. 21.
    Reithofer, M.R., Valiahdi, S.M., Jakupec, M.A., Arion, V.B., Egger, A., Galanski, M., Keppler, B.K.: Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. J. Med. Chem. 50, 6692–6699 (2007)CrossRefPubMedGoogle Scholar
  22. 22.
    Dhar, S., Daniel, W.L., Giljohann, D.A., Mirkin, C.A., Lippard, S.J.: Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J. Am. Chem. Soc. 131, 14652–14653 (2009)CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Dhar, S., Liu, Z., Thomale, J., Dai, H., Lippard, S.J.: Targeted single-wall carbon nanotube-mediated Pt(IV) prodrug delivery using folate as a homing device. J. Am. Chem. Soc. 130, 11467–11476 (2008)CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Mukhopadhyay, S., Barnes, C.M., Haskel, A., Short, S.M., Barnes, K.R., Lippard, S.J.: Conjugated platinum(IV) peptide complexes for targeting angiogenic tumor vasculature. Bioconjugate Chem. 19, 39–49 (2007)CrossRefGoogle Scholar
  25. 25.
    Feazell, R.P., Nakayama-Ratchford, N., Dai, H., Lippard, S.J.: Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J. Am. Chem. Soc. 129, 8438–8439 (2007)CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Tiefenbrunn, T.K., Dawson, P.E.: Chemoselective ligation techniques: Modern applications of time-honored chemistry. J. Pept. Sci. 94, 95–106 (2010)CrossRefGoogle Scholar
  27. 27.
    Hermanson, G.T.: Bioconjugate Techniques, 2nd edn, p. 1202. Academic Press, New York (2008)Google Scholar
  28. 28.
    Dirksen, A., Dawson, P.E.: Rapid oxime and hydrazone ligations with aromatic aldehydes for biomolecular labeling. Bioconjugate Chem. 19, 2543–2548 (2008)CrossRefGoogle Scholar
  29. 29.
    Prescher, J.A., Bertozzi, C.R.: Chemistry in living systems. Nat. Chem. Biol. 1, 13–21 (2005)CrossRefPubMedGoogle Scholar
  30. 30.
    Lim, L.H.K., Pervaiz, S.: Annexin 1: the new face of an old molecule. FASEB J 21, 968–975 (2007)CrossRefPubMedGoogle Scholar
  31. 31.
    Silistino-Souza, R., Rodrigues-Lisoni, F.C., Cury, P.M., Maniglia, J.V., Raposo, L.S., Tajara, E.H., Christian, H.C., Oliani, S.M.: Annexin 1: Differential expression in tumor and mast cells in human larynx cancer. Int. J. Cancer 120, 2582–2589 (2007)CrossRefPubMedGoogle Scholar
  32. 32.
    Dirksen, A., Hackeng, T.M., Dawson, P.E.: Nucleophilic catalysis of oxime ligation. Angew. Chem. Int. Ed. 45, 7581–7584 (2006)CrossRefGoogle Scholar
  33. 33.
    O’Ferrall, R.A.M., O’Brien, D.: Rate and equilibrium constants for hydrolysis and isomerization of (E)- and (Z)-p-methoxybenzaldehyde oximes. J. Phys. Org. Chem. 17, 631–640 (2004)CrossRefGoogle Scholar
  34. 34.
    Lustig, E.: A nuclear magnetic resonance study of syn-anti isomerism in ketooximes. J. Phys. Chem. 65, 491–495 (1961)CrossRefGoogle Scholar
  35. 35.
    Blanden, A.R., Mukherjee, K., Dilek, O., Loew, M., Bane, S.L.: 4-aminophenylalanine as a biocompatible nucleophilic catalyst for hydrazone ligations at low temperature and neutral pH. Bioconjugate Chem. 22, 1954–1961 (2011)CrossRefGoogle Scholar
  36. 36.
    Masui, M., Ohmori, H.: Studies on Girard hydrazones. Part III. Further kinetic studies on the hydrolysis of Girard hydrazones. J. Chem. Soc. B 762–771 (1967)Google Scholar
  37. 37.
    Dirksen, A., Dirksen, S., Hackeng, T.M., Dawson, P.E.: Nucleophilic catalysis of hydrazone formation and transimination: implications for dynamic covalent chemistry. J. Am. Chem. Soc. 128, 15602–15603 (2006)CrossRefPubMedGoogle Scholar
  38. 38.
    Carr, J., Tingle, M., McKeage, M.: Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother. Pharmacol. 50, 9–15 (2002)CrossRefPubMedGoogle Scholar
  39. 39.
    Carr, J., Tingle, M., McKeage, M.: Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro. Cancer Chemother. Pharmacol. 57, 483–490 (2006)CrossRefPubMedGoogle Scholar
  40. 40.
    Gibson, D.: The mechanism of action of platinum anticancer agents-what do we really know about it? Dalton Trans. 48, 10681–10689 (2009)CrossRefGoogle Scholar
  41. 41.
    Aryal, S., Hu, C.-M.J., Zhang, L.: Polymer–cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 4, 251–258 (2009)CrossRefGoogle Scholar
  42. 42.
    Kalia, J., Raines, R.T.: Hydrolytic stability of hydrazones and oximes. Angew. Chem. Int. Ed. 47, 7523–7526 (2008)CrossRefGoogle Scholar
  43. 43.
    Kuroda, R., Ismail, I.M., Sadler, P.J.: X-ray and NMR studies of trans-dihydroxo-platinum(IV) antitumor complexes. J. Inorg. Biochem. 22, 103–117 (1984)CrossRefPubMedGoogle Scholar
  44. 44.
    Dhara, S.C.: A rapid method for the synthesis of cis-[Pt(NH3)2Cl2]. Indian J. Chem. 8, 193–194 (1970)Google Scholar
  45. 45.
    Fulmer, G.R., Miller, A.J.M., Sherden, N.H., Gottlieb, H.E., Nudelman, A., Stoltz, B.M., Bercaw, J.E., Goldberg, K.I.: NMR chemical shifts of trace impurities: Common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist. Organometallics 29, 2176–2179 (2010)CrossRefGoogle Scholar
  46. 46.
    Sadowski, J., Gasteiger, J., Klebe, G.: Comparison of automatic three-dimensional model builders using 639 X-ray structures. J. Chem. Inf. Model. 34, 1000–1008 (1994)CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of ChemistryNational University of SingaporeSingaporeSingapore

Personalised recommendations